Although c-MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER-positive breast cancer

Tamoxifen (TAM) resistance is a major challenge in the treatment of estrogen receptor-positive (ER(+)) breast cancer. To date, to the best of our knowledge, there are only a few studies available examining the response of patients with TAM-resistant breast cancer to chemotherapy, and the guidelines...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Oncol
Egile Nagusiak: Chen, Rui, Guo, Shipeng, Yang, Chengcheng, Sun, Lu, Zong, Beige, Li, Kang, Liu, Li, Tu, Gang, Liu, Manran, Liu, Shengchun
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: D.A. Spandidos 2020
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7050981/
https://ncbi.nlm.nih.gov/pubmed/32319562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2020.4987
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak